POST-KALA-AZAR DERMAL LEISHMANIASIS
Clinical trials for POST-KALA-AZAR DERMAL LEISHMANIASIS explained in plain language.
Never miss a new study
Get alerted when new POST-KALA-AZAR DERMAL LEISHMANIASIS trials appear
Sign up with your email to follow new studies for POST-KALA-AZAR DERMAL LEISHMANIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a common parasite drug tackle a stubborn skin disease?
Disease control CompletedThis early-stage trial tested whether ivermectin, a well-known anti-parasitic drug, could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can spread the parasite causing kala-azar. Thirty adults in Bangladesh received either ivermectin or the standa…
Matched conditions: POST-KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated May 26, 2026 11:09 UTC
-
Old drug, new hope? ivermectin tested for stubborn leishmaniasis rash
Disease control CompletedThis small study tested the safety and effectiveness of the drug ivermectin for people with a skin condition called PKDL, which can appear after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL skin rashes took ivermectin pills for three months. The go…
Matched conditions: POST-KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated May 22, 2026 14:01 UTC